Carbapenem-Sparing Strategies for ESBL Producers: When and How
Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections. The spread of ESBL constitutes a major threat for public health, and infections with ESBL-prod...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Revisão |
| Language: | English |
| Published: |
2020
|
| Online Access: | https://doi.org/10.3390/antibiotics9020061 https://www.mdpi.com/2079-6382/9/2/61/pdf?version=1580901078 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1838465085720231936 |
|---|---|
| access_facet | Acesso Aberto |
| author | Ilias Karaiskos Helen Giamarellou |
| author_facet | Ilias Karaiskos Helen Giamarellou |
| cited_by_count_is | 124 |
| collection | OpenAlex |
| description | Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections. The spread of ESBL constitutes a major threat for public health, and infections with ESBL-producing organisms have been associated with poor outcomes. Established therapeutic options for severe infections caused by ESBL-producing organisms are considered the carbapenems. However, under the pressure of carbapenem overuse and the emergence of resistance, carbapenem-sparing strategies have been implemented. The administration of carbapenem-sparing antibiotics for the treatment of ESBL infections has yielded conflicting results. Herein, the current available knowledge regarding carbapenem-sparing strategies for ESBL producers is reviewed, and the optimal conditions for the "when and how" of carbapenem-sparing agents is discussed. An important point of the review focuses on piperacillin-tazobactam as the agent arousing the most debate. The most available data regarding non-carbapenem β-lactams (i.e., ceftolozane-tazobactam, ceftazidime-avibactam, temocillin, cephamycins and cefepime) are also thoroughly presented as well as non β-lactams (i.e., aminoglycosides, quinolones, tigecycline, eravacycline and fosfomycin). |
| format | Revisão |
| frbr_group_id_str | doi-10.3390/antibiotics9020061 |
| id | openalex-W3005306426 |
| institution | Hygeia Hospital |
| issn_str | 2079-6382 |
| issue_str | 2 |
| journal_title_str | Antibiotics |
| language | eng |
| publishDate | 2020 |
| publisher_str | Multidisciplinary Digital Publishing Institute |
| spellingShingle | Carbapenem-Sparing Strategies for ESBL Producers: When and How Ilias Karaiskos Helen Giamarellou |
| title | Carbapenem-Sparing Strategies for ESBL Producers: When and How |
| title_full | Carbapenem-Sparing Strategies for ESBL Producers: When and How |
| title_fullStr | Carbapenem-Sparing Strategies for ESBL Producers: When and How |
| title_full_unstemmed | Carbapenem-Sparing Strategies for ESBL Producers: When and How |
| title_short | Carbapenem-Sparing Strategies for ESBL Producers: When and How |
| topic_facet | Tigecycline Cefepime Carbapenem Tazobactam Medicine Intensive care medicine Fosfomycin Antibiotics Piperacillin/tazobactam Piperacillin Imipenem Microbiology Antibiotic resistance Biology Bacteria Genetics Pseudomonas aeruginosa |
| url | https://doi.org/10.3390/antibiotics9020061 https://www.mdpi.com/2079-6382/9/2/61/pdf?version=1580901078 |
| volume_str | 9 |